Navigation Links
Hard-to-Treat Leukemia Cell Subtype Identified
Date:1/14/2009

Discovery suggests new treatments for aggressive form of childhood disease, study says

WEDNESDAY, Jan. 14 (HealthDay News) -- Researchers say they may have identified a subtype of T-lymphoblastic leukemia (T-ALL) in children that does not respond to standard intensive chemotherapy.

Approximately 20 percent of children with T-ALL fair poorly on the same chemotherapy treatments that cure others with the disease, and doctors had been unable to explain why and which patients were least likely to improve.

Reporting online Jan. 14 and in the February edition of The Lancet Oncology, a team at St. Jude Children's Research Hospital in Memphis, Tenn., found that those who didn't respond to treatment had early T-cell precursors (ETPs). Believed to be recent migrants from the bone marrow to the thymus, they are substantially different to the lymphoid cells that standard chemotherapy normally attacks and may be resistant to it, the researchers said.

In a U.S.-based group of study participants, nearly three-quarters of those with ETP-ALL suffered a relapse within a decade, compared with only 10 percent of typical T-ALL patients. In an Italian group of participants, 57 percent of ETP-ALL patients had a relapse within two years, compared with only 14 percent of typical T-ALL patients.

"The high risk of remission failure or subsequent relapse for patients with ETP-ALL, if treated with standard intensive chemotherapy, indicates the need for alternative approaches to treatment," Dr. Dario Campana of St. Jude's department of oncology, said in a news release issued by the journal.

Campana and his team suggested trying alternate treatments for ETP-ALL, such as myeloablative therapy (high-dose chemotherapy) followed by haemopoietic stem-cell transplantation in first remission while other therapies are investigated.

More information

The U.S. National Cancer Institute has more about childhood leukemia.



-- Kevin McKeever



SOURCE: The Lancet Oncology, news release, Jan. 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Revolutionary New Technique Uses Onyx to Fill Hard-To-Treat Aneurysms
2. Relaxation training may improve control of hard-to-treat systolic hypertension
3. Blood-clotting protein modified for people with hard-to-treat hemophilia
4. Tackling Hard-to-treat Childhood Cancer by Targeting Epigenetic Changes
5. Tackling a hard-to-treat childhood cancer by targeting epigenetic changes
6. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
7. Study finds heart failure is rare among leukemia patients on imatinib
8. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. Novel strategy under study for aggressive leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hard-to-Treat Leukemia Cell Subtype Identified
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/18/2017)... ... January 18, 2017 , ... During ... disease to enamel erosion, and those dental problems can increase the risk of ... many pregnant women are failing to get the dental care they need. Agoura ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone wants less ... best drug option for each patient. Dentists have several general anesthesia alternatives and finding ... Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find out which ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and researchers who ... who desire a more intimate review and analysis of its highlights, a novel half-day, ... being offered by Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/17/2017)... Jan. 17, 2017 North America Insulin Delivery ... report, "North America Insulin Delivery Market Outlook to 2022", ... Delivery market. The report provides value, in millions of ... within market segments - Insulin Pens, Insulin Pumps, Insulin ... also provides company shares and distribution shares data for ...
Breaking Medicine Technology: